Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with Plasmodium falciparum malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan Africa

BACKGROUND: The novel anti-malarial cipargamin (KAE609) has potent, rapid activity against Plasmodium falciparum. Transient asymptomatic liver function test elevations were previously observed in cipargamin-treated subjects in two trials: one in malaria patients in Asia and one in volunteers with ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Ndayisaba, Gilles, Yeka, Adoke, Asante, Kwaku Poku, Grobusch, Martin P., Karita, Etienne, Mugerwa, Henry, Asiimwe, Stephen, Oduro, Abraham, Fofana, Bakary, Doumbia, Seydou, Jain, Jay Prakash, Barsainya, Sarita, Kullak-Ublick, Gerd A., Su, Guoqin, Schmitt, Esther K., Csermak, Katalin, Gandhi, Preetam, Hughes, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686384/
https://www.ncbi.nlm.nih.gov/pubmed/34930267
http://dx.doi.org/10.1186/s12936-021-04009-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686384/
https://www.ncbi.nlm.nih.gov/pubmed/34930267
http://dx.doi.org/10.1186/s12936-021-04009-1

Ejemplares similares